Introduction
It has long been known for over 20 years that cycloxygenase (COX) and lipoxygenase (LOX) enzymes metabolize arachidonic acid (AA) to prostaglandins, prostacyclin, thromboxane and leukotrienes and that these products play an important role in regulation of vascular tone Correspondence to: Noriyuki Miyata, Ph.D., Medicinal Pharmacology Laboratory, Medicinal Research Laboratories, Taisho Pharmaceutical Co., Ltd., 1-403 Yoshino-cho, Kita-ku, Saitama-city, Saitama 331-9530, Japan Phone: +81-48-669-3089 Fax: +81-48-652-7254 e-mail: noriyuki.miyata@po.rd.taisho.co.jp and inflammatory and airway response (Needleman et al., 1986) . In 1981, Capdevilla and colleagues (1981) first reported that AA can be also be metabolized by cytochrome P450 (P450) enzymes in the liver. Subsequent studies revealed that AA is metabolized by P450 enzymes to 19-and 20-hydroxyeicosatetraenoic acids (HETE), epoxyeicosatrienoic acids (EETs) and corresponding DiHETEs in the brain, lung, kidney and peripheral blood vessels. Indeed, P450 enzymes have emerged as the 3 rd pathway of AA metabolism and the metabolites formed are now known to play pivotal roles in the regulation of vascular tone in renal, cerebral, coronary and pulmonary circulation (McGiff and Quilley, 1999; Fleming, 2001; Roman, 2002) . Knowledge in this field has been exploding since the recent discovery of selective inhibitors of the synthesis of 20-HETE. This review summarizes the recent findings implicating the role of 20-HETE in the regulation of vascular tone in the cerebral, coronary and renal circulations with emphasis on pathological conditions.
Formation of 20-HETE
Cytochrome P450 enzymes of the 4A and 4F families catalyze the ω-hydroxylation of arachidonic acid and produce 20-HETE when incubated with AA (Hardwick et al., 1987; Powell et al., 1998; Gibson 1989; Kimura et al., 1989a, b; Simpson 1997) (Fig. 1 ). CYP4A10 and CYP4A12 catalyze the formation of 20-HETE in kidney and liver of mice (Heng et al., 1997) . CYP4A14 is also expressed in mouse kidney (Honeck et al., 2000) . CYP4F14, 4F15 and 4F16 are expressed in the liver of mice (Kikuta et al., 2000; Cui et al., 2001) . These isoforms catalyze the ω-hydroxylation of leukotrienes. However, little is known about the activity of these enzymes to produce 20-HETE from AA. In rats, CYP4A1, 4A2, 4A3 and 4A8 are expressed in kidney, cerebral blood vessels and liver (Hardwick et al., 1987; Helvig et al., 1998; Kimura et al., 1989a, b; Ito et al., 1998; Gebremedhin et al., 2000) . All of these isoforms have now been shown to produce 20-HETE from AA. CYP4F2, 4F3, 4F11, 4F12 and 4A11 are expressed in the liver and kidney of man (Kikuta et al., 1994; Powell et al., 1998; Lasker et al., 2000) . Among these isoforms, CYP4F2, CYP4A11 and CYP4F3B are thought to be major 20-HETE synthesizing enzymes (Powell et al., 1998; Lasker et al., 2000; .
Inhibitors of the synthesis or actions of 20-HETE
Several nonselective and selective inhibitors of 20-HETE synthesizing enzyme are known currently (Fig. 2) . 17-Octadecynoic acid (17-ODYA) was originally designed to be a specific suicide substrate inhibitor of the ω-hydroxylation of AA (Muerhoff et al., 1989) . It has been widely used to investigate the role of CYP metabolites of AA in the regulation of vascular Abbreviations: AA, arachidonic acid; ABT, 1-aminobenzotriazole; CSF, cerebrospinal fluid; 20-HETE, 20-hydroxyeicosatetraenoic acid; SAH, subarachnoid hemorrhage; phenyl-N'-hydroxyimido formamide; WIT0002, 20-hydroxy-6(Z), 15(Z)-dienoic acid; 17-ODYA, 17-octadecynoic acid; HET0016, N-hydroxy-N'-(4-butyl-2-methylphenyl)-formamidine; rCBF, regional cerebral blood flow; P450, cytochrome P450; MCAO, middle cerebral artery occlusion; 10-SUYS, sodium 10-undecynyl sulfate; TTC, 2,3,5-triphenyltetrazolium chloride.
function. However, the 17-ODYA is not a specific inhibitor of the formation of 20-HETE and it is equally effective at inhibiting the formation of EETs, a vasodilator metabolite of AA as it is in inhibiting the formation of 20-HETE Miyata et al., 2001) . 1-Aminobenzotriazole 1-aminobenzotriazol; DDMS: dibromododecenyl methylsulfonimide; DBDD: dibromododecenoic acid; 10-SUYS: sodium 10-undecynyl sulfate; HET0016: Nhydroxy-N'-(4-butyl-2-methylphenyl)-formamidine; phenyl-N'-hydroxyimido formamide. CYP4A: cytochrome P450 4A; CYP4F: cytochrome P450 4F.
(1-ABT) has been widely used as an inhibitor of the formation of 20-HETE. Its ability to inhibit CYP enzymes depends on the catalytic formation of benzyne (Ortiz de Montellano Su et al., 1998) . However, 1-ABT is not a very potent inhibitor of the formation of 20-HETE and it also inhibits the formation of EETs and a variety of other CYP isoforms (Mathew et al., 1985; Miyata et al., 2001) . Subsequently, Dr. John R. Falck (University of Texas Southwestern Medical Center) synthesized a more selective inhibitor of 20-HETE syntheses, Nmethyl-sulphonyl-12, 12-dibromododec-11-enamide (DDMS) and 12,12-dibromododec-11-enoic acid (DBDD). Wang et al. (1998) reported that DDMS and DBDD selectively inhibited the ω-hydroxylation of AA with an IC50 values of 2 µM, whereas the IC50 values for epoxidation were 60 and 51 µM. Xu and colleagues (2002) later reported that 10-undecynyl sulfate (10-SUYS) inhibited the formation of 19-and 20-HETE with an IC50 value of 15.7 µM and 10.1 µM in renal cortical microsomes, whereas epoxygenase activity was not affected at concentration up to 50 µM. They also reported that an intraperitoneal administration of 10-SUYS inhibited the renal formation of 20-HETE and acutely decreased mean arterial blood pressure in spontaneously hypertensive rats (SHR). Miyata et al. (2001) subsequently discovered a potent and selective inhibitor of 20-HETE synthesizing enzyme, N-hydroxy-N'-(4-butyl-2-methyl-phenyl)-formamidine (HET0016) using a high throughput screening of the compound library of the Taisho Pharmaceutical Co., Ltd Sato et al., 2001) . HET0016 inhibits the formation of 20-HETE by rat renal microsomes with an IC50 value of 35 nM. The IC50 value for inhibition of the formation of EETs is 2800 nM. Several analogs with the ability to very selectively inhibit the formation of 20-HETE were also reported (Nakamura et al., 2003; 2004a, b, c) . Most recently, the properties of TS-011 (N-(3-Chloro-4-morpholin-4-yl) phenyl-N'-hydroxyimido formamide) have been described. To date, TS-011 is the most potent and selective inhibitor of the synthesis of 20-HETE . Dr. Falck (University of Texas Southwestern Medical Center) has synthesized a large number of 20-HETE analogs. One of these compounds, 6(Z),15(Z) 20-hydroxyeicosadienoic acid (WIT0002), was found to be a competitive antagonist of the vasoconstrictor actions of 20-HETE, whereas 5(Z),14(Z) 20-hydroxyeicosadienoic acid serves as a stable 20-HETE agonist that cannot be metabolized by COX or LOX enzymes (Alonso-Galicia et al., 1999; Yu et al., 2003) .
Vasoconstrictor effects of 20-HETE
20-HETE is a potent constrictor or renal, cerebral and mesenteric arteries (Harder et al., 1994; Gebremedhin et al., 1998 Gebremedhin et al., , 2000 Zou et al., 1994) . The vasoconstrictor response to 20-HETE is associated with activation of protein kinase C (Lange et al., 1997; Obara et al., 2002) , Rho kinase and the mitogen activated protein (MAP) kinase pathway (Sun 1999 , Muthalif et al., 1998 2000a,b; Randriambozvonjy et al., 2003) . 20-HETE also increases intracellular Ca 2+ by causing the depolarization of vascular smooth muscle membrane secondary to blocking the large-conductance Ca 2+ -activated K + -channels (Harder et al., 1994; Imig et al., 1996; Lange et al., 1997 , Gebremedhin et al., 1998 and by a direct effect on L-type Ca channels (Gebremendin et al., 1999) . Previous studies have indicated the elevations in the production of 20-HETE mediate the myogenic response of skeletal, renal and cerebral arteries to elevations in transmural pressure (Harder et al., 1994; Imig et al., 1994; Gebremedhin et al., 2000; Frisbee et al., 2001a, b) . Blockade of the formation of 20-HETE impairs autoregulation of both renal and cerebral blood flow in vivo (Gebremedhin et al., 2000) . Recently, Mulligan and MacVicar (2004) have shown that norepinephrine increased intracellular Ca 2+ in the astrocyte endfeet, the peak of which preceded the onset of arteriole constriction. Vasoconstrictions induced in the cerebrovasculature by increased intracellular Ca 2+ in astrocyte endfeet are generated through the phospholipase A2-arachidonic acid pathway and 20-HETE production because the increase in intracellular Ca 2+ were inhibited by the treatment of HET0016 an inhibitor of 20-HETE synthesis.
There is an important interaction between nitric oxide (NO) and the formation of 20-HETE production. NO inhibits the formation of 20-HETE formation in renal and cerebral arteries and that a fall in levels of 20-HETE contributes the cyclic GMP-independent dilator effect of NO to activate the large-conductance Ca 2+ -activated K + -channels and to dilate the cerebral arteries Sun et al., 1998; Sun et al., 2000) .
Role of 20-HETE in the control of the cerebral vascular tone in stroke
Eighty percent of strokes are ischemic and 20% are hemorrhagic. Hemmorrhagic stroke commonly occurs after rupture of aneurysms or head trauma. There is an initial period of cerebral ischemia lasting several hours due to the rise in cerebral spinal fluid (CSF) pressure and the development of acute cerebral vasospasm. Many studies have examined that role of vasoconstrictor pathways in mediating cerebral vasospasm after subarachnoid hemorrhage (SAH). The levels of endothelin, thromboxane A2 and 5-HT are elevated in CSF after SAH (Seifert et al., 1995; Juvela 2000; Pickard et al., 1994; Saida et al., 1997; Cambj-Sapunar et al., 2003) . It is proposed that these vasoconstrictors are possible mediators of cerebral vasospasm following SAH. However, the factors that contribute to the acute fall in cerebral blood flow following SAH remain uncertain.
Recent studies have indicated that 20-HETE may also contribute to the development of vasospasm following SAH. The levels of 20-HETE in CSF increase in acute phase following SAH in rats (Kehl et al., 2002 , Cambj-Sapunar et al., 2003 . Inhibition of the synthesis of 20-HETE, with 17-ODYA or HET0016 prevents the acute fall in cerebral flow and increase in levels of 20-HETE levels in CSF following SAH. WIT0002, a functional antagonist of 20-HETE also prevents the acute fall in cerebral blood flow after SAH and WIT0003 an agonist of 20-HETE potentiates the fall in cerebral blood flow following SAH (Yu et al., 2004) . Excitingly, there is an interaction between 5-HT and 20-HETE. Intracisternal injection of 5-HT mimicks SAH by increasing 20-HETE levels in CSF and reducing regional cerebral blood flow (rCBF) by 30%. Blockade of the synthesis of 20-HETE with HET0016 prevents the fall in rCBF produced by 5-HT. The authors suggest that the release of 5-HT after SAH activates 5-HT1B receptors and the synthesis of 20-HETE and that 20-HETE contributes to the acute fall in rCBF by potentiating the vasoconstrictor response of cerebral vessels to 5-HT (Cambj-Sapunar et al., 2003) . Previous studies have shown that human polymorphonuclear leukocytes (PMNs) can produce 20-HETE when incubated with AA (Rosolowsky and Campbell, 1996; Hill and Murphy, 1992; Bednar et al., 2000) .
There is also a recent report that blockade of the synthesis of 20-HETE can reverse delayed vasospasm in dogs subjected to the dual hemorrhage model (Hacein-Bey et al., 2004a) . 20-HETE levels in CSF from patients with SAH were higher than that from control subject (HaceinBey et al., 2004b) . Therefore, increase in levels of 20-HETE in CSF, vascular smooth muscles and PMNs may be involved in acute fall in cerebral blood flow after SAH.
We have shown that TS-011, an inhibitor of the synthesis of 20-HETE reduces infarct volume in middle cerebral artery occlusion model of ischemic stroke (Fig. 3) as well as the collagenase-induced intracerebral hemorrhage models . Furthermore, intracarotid arterial injection of 20-HETE also can produce an ischemic stroke and neurologic deficits . These findings suggest that 20-HETE may contribute to the loss of neurons following ischemic stroke perhaps by reducing collateral flow. These results also indicate that blockade of the synthesis and/or actions of 20-HETE may be useful in limiting cerebral ischemia and injury to the brain following SAH and other conditions associated with intracerebral hemorrhage.
Coronary circulation
20-HETE has been reported to be an endothelium-independent and COX-dependent dilator of bovine coronary arteries (Pratt et al., 1998) . On the other hand, 20-HETE is a potent constrictor of small coronary arteries in pigs (Randriamboavonjy et al., 2003) . The endotheliumdependent constriction induced by 20-HETE was partially inhibited by the COX inhibitor diclofenac, the thromboxane and endoperoxide receptor antagonist SQ29548, and the thromboxane A2 synthase inhibitor furegrelate. 20-HETE production was increased two-and threefold over basal levels in response to isometric stretch or the thromboxane analogue U46619, respectively, and was inhibited by the CYP 4A inhibitor DDMS (Randriamboavonjy et al., 2005) . Removal of endothelium attenuated the vasoconstrictor response to 20-HETE, whereas preconstriction of endothelium-denuded vessels to 25% of the maximum response with KCl markedly enhanced the response to 20-HETE. 20-HETE-induced contraction was abolished by the Rho-kinase inhibitor Y27632, but was insensitive to the PKC inhibitor RO 31-8220. These data suggest that in small porcine coronary arteries, 20-HETE can induce vasoconstriction by two mechanisms, one is endothelium-dependent and involves the COX-dependent generation of vasoconstrictor prostanoids, and the other which is endothelium-independent. The latter response is associated with the activation of Rho-kinase.
It is well-known that the endothelial cells release NO and prostacyclin in response to acetylcholine, bradykinin etc. These factors are thought to be endothelium-derived relaxation factor (EDRF). There is considerable evidence that EETs, CYP metabolites of AA, are also made by the endothelium and are potent vasodilators that hyperpolarize vascular smooth muscle membranes by activating Ca 2+ -activated K + -channels Zou et al. were first in 1992 and Campbell et al., 1996; Popp et al., 1996; Eckman et al., 1998; Hayabuchi et al., 1998; Miura and Gutterman, 1998; Fisslthaler et al., 1999; Fleming et al., 2001 ).
Subsequent studies have indicated that blockade of the formation of EETs impair EDHF mediated dilation in some vascular beds but not others. As such most investigators consider that EETs likely serve as one of the EDHF but it is clear that there are other factors that can mediate these responses in the absence of EETs. 20-HETE can interact with EET-mediated responses. Endogenously generated 20-HETE inhibits EDHF-mediated relaxation of coronary arteries (Randriamboavonjy et al., 2005) .
Exogenous application of 20-HETE inhibited EDHF-mediated relaxations and caused a concomitant increase in the phosphorylation of protein kinase C alpha (PKC alpha). This effect was reversed by the PKC inhibitor Ro-31-8220 and mimicked by the PKC activator phorbol-12-myristate-13-acetate. These results indicate that vascular tone in small porcine coronary arteries is partly regulated by the endogenous production of 20-HETE. In addition, 20-HETE functionally antagonizes EDHF-mediated relaxation of coronary arteries via a PKC alphadependent mechanism, probably involving the inhibition of the Na + -K + -ATPase.
Recently, Nithipatikom and co-workers (2001) reported that CYP4A isoforms, which are known to produce 20-HETE are expressed in the heart. Inhibitors of the synthesis of 20-HETE markedly reduced infarct size following ischemia and reperfusion of the heart Gross et al., 2004) . Exogenous administration of 20-HETE in the coronary arteries increased infarct size . These results indicate an important role for 20-HETE in exacerbating myocardial injury following coronary ischemia. 
Renal circulation
CYP4A1, 4A2, 4A3 and 4A8 are expressed in the kidney of rats and CYP4A11 and CYP4F2 are expressed in human kidney. These 20-HETE synthesizing enzymes are expressed at high levels in the proximal tubule, preglomerular arterioles and thick ascending loop of Henle. 20-HETE is a potent constrictor of renal arteries. Alonso-Galicia et al., 1999; Sun et al., 1999; . It also acts as a second messenger and potentiates the actions of other vasoconstrictor substances. Several studies indicate that that angiotensin II stimulates the release of 20-HETE in isolated perfused rabbit kidney (Carroll et al., 1996 (Carroll et al., , 1997 . Croft and coworkers (2000) also demonstrated that angiotensin II stimulates the formation of 20-HETE in rat renal preglomerular vessels. Inhibition of the formation of 20-HETE attenuates the vasoconstrictor response to angiotensin II by ~50% in rat renal interlobular artery and its pressor response in anesthetized rats (Alonso-Galicia et al., 2002) . A similar observation was found in the response to endothelin-1. Endothelin-1 stimulates the formation of 20-HETE in isolated rat perfused kidney (Oyekan et al., 1997; Hercule and Oyekan, 2000; Imig et al., 2000) . Quilley et al. (2003) also showed that U46619, an analog of thromboxane A2 stimulated the production of 20-HETE and released 20-HETE partially act as a second messenger to cause vasoconstriction in rat perfused kidney.
On the other hand, 20-HETE plays an important role in the regulation of tubular sodium reabsorption. 20-HETE inhibits Na + -K + -ATP-ase activity (Schwartzman et al., 1985) and sodium transport in rabbit proximal tubule (Quigley et al., 2000) . 20-HETE is also the major metabolite of AA in thick ascending limb of the Henle (TALH) and inhibits Na + -K + -2Cl -co-transport in this nephron segment (Escalante et al., 1991; Carroll et al., 1991, Ito and . Recently, McCarthy and co-workers reported that 20-HETE inhibited the in vitro albumin permeability induced by puromycin aminonucleoside (PAN) in isolated glomerulus (McCatthy et al., 2005) . Clofibrate, an inducer of CYP4A also inhibited PAN-induced albumin permeability in glomerulus. Furthermore, the renal expression of transforming growth factor-β (TGFβ) doubles in Dahl-salt sensitive (Dahl S) rats fed a high-salt diet for 7 days, and this is associated with a marked rise in P(alb) and changes in the ultrastructure of the glomerular filtration barrier (Dahly-Vernon et al., 2005) . Chronic treatment of Dahl S rats with a TGFβ neutralizing antibody prevented the increase in glomerular albumin permeability and preserved the structure of glomerular capillaries. Preincubation of glomeruli isolated from Sprague Dawley rats with TGFβ (10 ng/mL) for 15 min increased glomerular albumin permeability. This was associated with inhibition of the glomerular production of 20-HETE. Pretreatment of glomeruli from Sprague-Dawley rats with a stable analog of 20-HETE, WIT0003 reduced glomerular albumin permeability and opposed the effects of TGFβ to increase glomerular albumin permeability (Fig.  4) . These results indicate that upregulation of the glomerular formation of TGFβ may contribute to the development of proteinuria and glomerular injury early in the development of hypertension by increasing albumin permeability secondary to inhibition of the glomerular production of 20-HETE. These results indicate that 20-HETE agonist or an inducer of the formation of 20-HETE may have a therapeutic potential to protect against hypertension-and diabetes-induced glomerular injury.
Androgen-induced regulation of 20-HETE production in hypertension
It is well known that there are marked gender differences in control of arterial blood pressure and susceptibility to cardiovascular disease. For example, arterial blood pressure is higher in male spontaneously hypertensive rats (SHR) than in females. Castration or blockade of androgen receptors attenuates the development of hypertension in male rats. Conversely, testosterone treatment increases arterial blood pressure in ovariectomized females and castrated males (Reckelhoff et al., 2001) . Ovariectomy of female SHR does not alter blood pressure. Androgens therefore seem to be a significant risk factor in development of hypertension.
Recently, Holla et al. (2001) uncovered a possible link between the expression of CYP4A enzymes and the development of androgen induced hypertension. They reported that knockout of the mouse CYP4A14 isoform that catalyzes the metabolism of lauric acid but does not produce 20-HETE increased plasma androgen concentration. This was associated with increased expression of CYP 4A12 and the formation of 20-HETE, and the animals became hypertensive. Castration prevented the arterial blood pressure increase and the enzyme induction, and androgen replacement restored the hypertension and CYP 4A12 enzyme activity. Although the link between CYP4A14 deletion and stimulation of androgen production remains to be determined these observations suggest that CYP4A enzymes control androgen levels and that andogens control the expression of CYP4A enzymes and influences arterial blood pressure. treatment of rats for 2 weeks with 5α-dihydrotestosterone increases the synthesis of 20-HETE in renal microsomes and in preglomerular blood vessels. Systolic blood pressure increased in male and female rats by 46 and 57 mmHg, respectively. These results are clearly consistent with the hypothesis that androgen-induced activation of 20-HETE production may influence blood pressure. Ishizuka and co-workers (2004) show that the renal production of 20-HETE was significantly greater in male SHR than in male Wistar-Kyoto (WKY) rats. The differences in the renal production of 20-HETE were consistent with the cytochrome CYP4A protein levels. Plasma freetestosterone levels in male SHR were twice as high as those in male WKY. Castration and treatment with the androgen receptor antagonist, flutamide, reduced blood pressure, the renal production of 20-HETE, and the renal expression of CYP4A protein in both strains. These results indicate that the renal production of 20-HETE and the expression of CYP4A both gender and strain dependent. On the other hand, Zhou et al. (2005) reported that an elevation of arterial blood pressure and a decrease of renal cortical 20-HETE production were found in male rats on high fat diet, but no arterial blood pressure changes were observed in female rats on high fat diet. The high fat treatment reduced the production of 20-HETE and decreased the expression of CYP4A enzyme in the proximal tubules of male rats. They show that there are gender-specific differences in regulation of renal eicosanoid synthesis, sodium balance, and arterial blood pressure caused by high fat treatment.
Involvement of 20-HETE production in toxemia of pregnancy
As mentioned-above, 20-HETE plays an important role in the regulation of tubular sodium reabsorption. In this respect, the renal production of 20-HETE is also altered in toxemia of pregnancy. Wang and co-workers (2002) have shown that renal microvessel 20-HETE synthesis increased by 50 and 82% in rats on days 6 and 12 of gestation, and it returns to control levels by day 19 of gestation. In contrast, 20-HETE synthesis thick ascending limb was unchanged from control levels on days 6 and 12 of gestation, but it increased two-fold on day 19 of gestation. This increase in 20-HETE production on day 19 of gestation was associated with a twofold increase in the urinary excretion of 20-HETE and it coincided with a 23 mmHg fall in blood pressure. Administration of the CYP4A inhibitor 1-ABT for 2 days on day 12 of pregnancy or for 5 days, starting on day 15 of pregnancy, caused a transient but significant reduction in systolic blood pressure. ABT treatment also decreased urinary sodium, urinary 20-HETE, and renal and microvessel 20-HETE synthesis. This study was the first to demonstrate that 20-HETE synthesis in the kidney was altered in time-and site-specific manner during pregnancy. Furthermore, they examined whether decreases in microvessel CYP4A1/CYP4A3 expression and 20-HETE synthesis is dependent on NO, the synthesis of which increases in late pregnancy (Wang et al., 2003) . Administration of N G -nitro-L-arginine methyl ester (L-NAME) to pregnant rats for 6 days (days 15-20 of pregnancy) caused a significant increase in systolic blood pressure, which was prevented by concurrent treatment with the CYP4A inhibitor 1-ABT.
Urinary NO2/NO3 excretion decreased by 40 and 52% in L-NAME-and L-NAME+ 1-ABTtreated groups, respectively. Interestingly, renal microvessel 20-HETE synthesis showed a marked increase following L-NAME treatment, and this increase was diminished with coadministration of 1-ABT. These results demonstrate that NO interacts with CYP4A proteins and it interferes with renal microvessel 20-HETE synthesis, which may play an important role in the regulation of blood pressure and renal function during pregnancy. Given the importance of 20-HETE in the control of renal function, it is likely that changes in this system contribute to the abnormalities in renal function that are associated with pregnancy.
Other pathological states
Upregulation of the expression of CYP4A protein and the renal production of 20-HETE have been observed in cyclosporine A-induced (Sacerdoti et al., 1991; Nakamura et al., 1994; and cisplatin-induced (Nakamura et al., 1998) nephrotoxicity. As shown in Fig. 5 , the urinary excretion of 20-HETE is elevated in rats treated with cyclosporine A . The increase in the urinary excretion of 20-HETE in the CsA treated rats was highly correlated with the increase in BUN levels (r=0.819, P<0.001) and urine volume (r=0.832, P<0.001). Urinary excretion of 20-HETE is also elevated in Bartter's syndrome (Watzer et al., 2000) , hepatorenal syndrome (Sacerdoti et al., 1997) , hypertension (Ward et al., 2005) , endothelial cells injury (Ward et al., 2004) . These findings suggest that alterations in the renal production of 20-HETE likely contributes to the changes in renal hemodynamics and tubular function associated with these conditions. Jiang and colleagues (2004) have also shown that over-expression of CYP4A1 in VSM promotes endothelial sprouting in renal arterial microvessels. They constructed adenoviruses expressing the CYP4A1 cDNA or LacZ under the control of the smooth muscle cell-specific promoter SM22alpha (Ad-SM22-4A1 and Ad-SM22-nLacZ, respectively). Arteries transduced with Ad-SM22-4A1 produced higher levels of 20-HETE and demonstrated a marked angiogenic activity measured as the total length of sprouting neovessels. This angiogenic activity represented endothelial cell sprouting and was fully blocked by treatment with HET0016, a selective inhibitor of CYP4A. The inhibitory effect of HET0016 was reversed by addition of a 20-HETE agonist.
They indicate that Ad-SM22-4A1 drives a smooth muscle-specific functional expression of CYP4A1 and demonstrates increased angiogenesis via increased production of 20-HETE.
More recently, Chen and colleagues (2005) reported that WIT0003, an agonist of 20-HETE induced mitogenesis in human umbilical vein endothelial cells (HUVECs) in vitro and angiogenesis in the rat cornea in vivo. They also reported that HET0016 also abolished the mitogenic response to VEGF in HUVECs and the angiogenic response to VEGF, basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) in vivo by 80 to 90%. DDMS, another selective inhibitor of the synthesis of 20-HETE also inhibited the angiogenic responses induced by VEGF. These findings indicate that 20-HETE plays a role in the angiogenic response to a variety of growth factors. These findings suggest that inhibitors of the synthesis of 20-HETE might have therapeutic potential to block angiogenesis in pathological condition such as cancer and retinopathy.
Conclusion
New information on the role of 20-HETE in the control of diverse physiological functions has been exponentially expanding due to the recent development of selective inhibitors of the synthesis of 20-HETE. The formation of 20-HETE is altered in a variety of diseases such as hypertension, cerebrovascular diseases, coronary heart disease, renal disease and pregnancy.
Already, inhibitors of 20-HETE have been shown to have beneficial effects in hemorrhagic and ischemic models of stroke and in reducing infact size in the heart. These findings suggest that drugs that modulate the formation of 20-HETE may have eventually be shown to have beneficial effects in treatment of a variety of diseases in man.
